ImmunoForge to Conduct Strategic Partnering at Bio-Europe Spring 2026

2026-03-12 - 09:38

Conducting global licensing partnering of LMT15, a proprietary BBB Shuttle platform Also discussing global out-licensing of Phase 2 stage new drugs PF1801 and PF1804 SEOUL, South Korea, March 12, 2026 /PRNewswire/ — ImmunoForge Co., Ltd., a biopharmaceutical company developing treatments for rare diseases, announced that they will participate in Bio-Europe Spring 2026, held in Lisbon,